PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)

被引：0
|
作者：
Saba, N. [1 ]
Youssoufian, H. [2 ]
Cohen, E. [3 ]
Singh, J. [4 ]
Makris, L. [5 ]
Perdomini, M. [6 ]
MacIntyre, S.
Denker, A. [7 ]
机构：
[1] Emory Univ, Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA
[2] Youssoufian Hagop, Med, Boston, MA USA
[3] UC San Diego Hlth, Med Dept, Moores Canc Ctr, La Jolla, CA USA
[4] AMR Kansas City Oncol, Med Dept, Kansas City, MO USA
[5] Stathmi, Stat, New Hope, PA USA
[6] Flamingo Therapeut, Clin Dev, Illkirch Graffenstaden, France
[7] Flamingo Therapeut, Clin Dev, Philadelphia, PA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
943TiP
引用
收藏
页码：S592 / S592
页数：1
相关论文
共 50 条
  • [1] PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC)
    Posner, Marshall R.
    Wong, Deborah J. L.
    Harrington, Kevin Joseph
    O'Neal, Richard Lee
    Makris, Lukas
    Perdomini, Morgane
    MacIntyre, Susan
    Denker, Andrew
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
  • [3] Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
    Cho, Byoung Chul
    Brana, Irene
    Cirauqui, Beatriz
    Aksoy, Sercan
    Couture, Felix
    Hong, Ruey-Long
    Miller Jr, Wilson H.
    Chaves-Conde, Manuel
    Teixeira, Margarida
    Leopold, Lance
    Munteanu, Mihaela
    Ge, Joy Yang
    Swaby, Ramona F.
    Hughes, Brett G. M.
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [4] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
    Burtness, Barbara
    Harrington, Kevin J.
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro, Gilberto, Jr.
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett G. M.
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Hong, Ruey-Long
    Mendoza, Rene Gonzalez
    Roy, Ananya
    Zhang, Yayan
    Gumuscu, Burak
    Cheng, Jonathan D.
    Jin, Fan
    Rischin, Danny
    LANCET, 2019, 394 (10212): : 1915 - 1928
  • [5] Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1epositive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial
    Fayette, J.
    Adkins, D. R.
    Psyrri, A.
    Siu, L. L.
    Tahara, M.
    William, W. Nassib, Jr.
    Pyle, R.
    Shen, Y-M.
    Zohren, F.
    Pennella, E.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S654 - S654
  • [6] Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma
    Harrington, K. J.
    William, W. N., Jr.
    Khilnani, A.
    Algazi, A. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S683
  • [7] Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
    Tamaskovics, B. F.
    Hecht, M.
    Schubert, P.
    Kallies, A.
    Illmer, T.
    Radke, J.
    Koelbl, O.
    Steger, F.
    Brunner, T. B.
    Roedel, C.
    Fleischmann, M.
    Reinacher-Schick, A.
    Wingender, L. F.
    Melchior, P.
    Klautke, G.
    Hintzen, U.
    Gaipl, U. S.
    Haussmann, J.
    Budach, W.
    Fietkau, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S593 - S593
  • [8] Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Chow, Laura Quan Man
    Mehra, Ranee
    Haddad, Robert I.
    Mahipal, Amit
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Le, Dung T.
    Muro, Kei
    Geva, Ravit
    Chung, Hyun Cheol
    Lin, Chia-Chi
    Ayers, Mark
    Aurora-Garg, Deepti
    Lunceford, Jared K.
    Cheng, Jonathan D.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
    Fayette, J.
    Thomas, G.
    Daste, A.
    Rotarski, M.
    Castelo, B.
    Rullan, A.
    Levine, A.
    Philipson, R. S.
    Harrington, K. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S615 - S616
  • [10] Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
    Kao, Hsiang-Fong
    Liao, Bin-Chi
    Huang, Yen-Lin
    Huang, Huai-Cheng
    Chen, Chun-Nan
    Chen, Tseng-Cheng
    Hong, Yuan-Jing
    Chan, Ching-Yi
    Chia, Jean-San
    Hong, Ruey-Long
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1560 - 1571
12345